Ipsen sees 3rd-qtr revenues growth of 22.6%, but shares fall

26 October 2017

Despite reporting significant sales growth for the third-quarter of 2017, French biopharma firm Ipsen (Euronext: IPN) saw its shares drop 6.43% to 105.50 euros in morning trading.

Group sales for the quarter grew 22.6% to 470.1 million euros ($555.2 million),driven by Specialty Care sales growth of 26.5% to 396.2 million eurosreflecting continued Somatuline (lanreotide)momentum and increasing contribution of new products Cabometyx (cabozantinib) and Onivyde (irinotecan), and solid Consumer Healthcare sales growth of 5.0% to 73.9 million euros.

Year-to-date group sales growth of 20.1% wasfueled by Specialty Care sales growth of 24.3%and Consumer Healthcare back to growth at 2.5%.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK